Danish drug maker Orphazyme has announced positive results from its Phase II/III trial of arimoclomol in rare genetic disease Niemann-Pick disease type C (NPC). The multi-centred, double-blind trial measured notable treatment difference between Niemann-Pick disease […]
Japanese pharma company Takeda has announced that its dengue vaccine candidate TAK-003 met its primary efficacy endpoint in a Phase III trial. Data from the Tetravalent Immunization against Dengue Efficacy Study (TIDES) found that TAK-003 […]
SMi presents its 13th annual Parallel Trade conference happening in just one week. The highly anticipated event provides the perfect platform for industry experts to come together and share perspectives on the practice of parallel […]
SMi Group’s next 11thannual conference is thrilled to welcome Heiko Goette, Biostatistician from Merck speaking about simulated development programs that are shaping state of the art adaptive design techniques. With the growing popularity in use […]
SMi reports:Senior industry experts are set to speak and present at the 10th Annual RNA Therapeutics Conference, taking place on 20th – 21st February 2019 in London in less than 4 weeks. With less than […]